Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study
Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study
复制标题
DOI：
10.1007/s00259-022-06101-3
复制
发表时间：
2023-01-05
影响因子：
9.1
通讯作者：
Zhu, Zhaohui
中科院分区：
文献类型：
--
作者：
Wang, Guochang;Li, Linlin;Zhu, Zhaohui
目的：这项前瞻性研究旨在评估和比较应用PSMA特异性示踪剂[Ga-68]Ga-P16-093和葡萄糖代谢探针2-[F-18]FDG的PET/CT对肾透明细胞癌(CcRCC)患者的诊断价值。方法：收集42例经手术病理证实的慢性肾细胞癌患者。在1周内，每个患者接受[Ga-68]Ga-P16-093和2-[F-18]FDGPET/CT检查。除肉眼分析肿瘤数目外，还测量标准化摄取值(SUV)以进行半定量比较和相关分析。结果：在原发性肾细胞癌患者中，与2-[F-18]FDGPET/CT相比，[Ga-68]Ga-P16-093PET/CT具有更高的检出率(19/22比13/22，P=0.031)和更高的肿瘤摄取率(15.7+/-9.0vs.5.1+/-3.4，P<；0.001)。原发肿瘤在[Ga-68]Ga-P16-093和2-[F-18]FDGPET/CT上的SUVmax与PT分期([Ga-68]Ga-P16-093，r=0.550，P=0.008；2-[F-18]FDG，r=0.514，P=0.014)和WHO/ISUP分级([Ga-68]Ga-P16-093，r=0.566，P=0.006；2-[F-18]FDG分别为r=0.492，P=0.020)。对于转移性肾细胞癌患者，[Ga-68]Ga-P16-093PET/CT的检出率(21/22vs.14/22，P=0.008)和肿瘤摄取率(11.0+/-6.4vs.4.4+/-2.7P<；0.001)也高于2-[F-18]FDGPET/CT。[Ga-68]Ga-P16-093PET/CT上的SUVmax与原发癌和转移性肾细胞癌中pSMA的表达显著相关(r=0.776，P<0.001)和转移性肾癌(r=0.626，P=0.029)。结论：对于肾细胞癌患者，[Ga-68]Ga-P16-093 PET/CT比2-[F-18]FDG PET/CT具有更好的肿瘤检出能力。
Purpose:This pilot study was prospectively designed to evaluate and compare the diagnostic value of PET/CT using a PSMA-specific tracer [Ga-68]Ga-P16-093 and a glucose metabolism probe 2-[F-18]FDG in clear cell renal cell carcinoma (ccRCC) patients. Methods:Forty-two pathologically confirmed ccRCC patients were included. Within 1 week, each patient underwent [Ga-68]Ga-P16-093 and 2-[F-18]FDG PET/CT. In addition to visual analysis of tumor number, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. Results:For primary ccRCC patients, [Ga-68]Ga-P16-093 PET/CT demonstrated a significantly higher detection rate (19/22 vs. 13/22, P = 0.031) and higher tumor uptake (15.7 +/- 9.0 vs. 5.1 +/- 3.4, P < 0.001) than 2-[F-18]FDG PET/CT. In addition, the SUVmax of the primary tumor on [Ga-68]Ga-P16-093 and 2-[F-18]FDG PET/CT was significantly correlated with pT stage (for [Ga-68]Ga-P16-093, r = 0.550, P = 0.008; for 2-[F-18]FDG, r = 0.514, P = 0.014) and WHO/ISUP grade (for [Ga-68]Ga-P16-093, r = 0.566, P = 0.006; for 2-[F-18]FDG, r = 0.492, P = 0.020), respectively. For metastatic ccRCC patients, [Ga-68]Ga-P16-093 PET/CT also demonstrated a better detection rate (21/22 vs. 14/22, P = 0.008) and higher tumor uptake (11.0 +/- 6.4 vs. 4.4 +/- 2.7, P < 0.001) than 2-[F-18]FDG PET/CT. The SUVmax on [Ga-68]Ga-P16-093 PET/CT had a significant association with PSMA expression in primary ccRCC (r = 0.776, P < 0.001) and metastatic ccRCC (r = 0.626, P = 0.029). Conclusions:[Ga-68]Ga-P16-093 PET/CT demonstrates significantly better tumor detectability than 2-[F-18]FDG PET/CT for ccRCC patients.